Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRα

Cell Metabolism

Volumn 1, Issue 5, 2005, Pages 297-308

  Lehrke, Michael ^a   Lebherz, Corinna ^a   Millington, Segan C ^a   Guan, Hong Ping ^a   Millar, John ^a   Rader, Daniel J ^a   Wilson, James M ^a   Lazar, Mitchell A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR STIMULATING AGENT; LIPID; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; CCAAT ENHANCER BINDING PROTEIN; CELL RECEPTOR; DNA BINDING PROTEIN; HYPOCHOLESTEROLEMIC AGENT; LIVER X RECEPTOR; MESSENGER RNA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; SREBF1 PROTEIN, HUMAN; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SULFONAMIDE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CHOLESTEROL DIET; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; ANIMAL; ARTERIOSCLEROSIS; BLOOD; C57BL MOUSE; COMPARATIVE STUDY; DIET; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER; METABOLISM; MOUSE MUTANT; TRANSGENIC MOUSE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CCAAT-ENHANCER-BINDING PROTEINS; DIET; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIPID METABOLISM; LIPIDS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SULFONAMIDES; TRANSCRIPTION FACTORS;

EID: 26944471737     PISSN: 15504131     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmet.2005.04.005     Document Type: Article

References (52)

1. Assmann G., and Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am. J. Cardiol. 70 (1992) 733-737
2. Barish G.D., and Evans R.M. PPARs and LXRs: atherosclerosis goes nuclear. Trends Endocrinol. Metab. 15 (2004) 158-165
3. Baroukh N., Bauge E., Akiyama J., Chang J., Afzal V., Fruchart J.C., Rubin E.M., Fruchart-Najib J., and Pennacchio L.A. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1297-1302
4. Chawla A., Repa J.J., Evans R.M., and Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science 294 (2001) 1866-1870
5. Chiang J.Y., Kimmel R., and Stroup D. Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene 262 (2001) 257-265
6. Chisholm J.W., Hong J., Mills S.A., and Lawn R.M. The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J. Lipid Res. 44 (2003) 2039-2048
7. DeBose-Boyd R.A., Ou J., Goldstein J.L., and Brown M.S. Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. Proc. Natl. Acad. Sci. USA 98 (2001) 1477-1482
8. Deeb S.S., Nevin D.N., Iwasaki L., and Brunzell J.D. Two novel apolipoprotein A-IV variants in individuals with familial combined hyperlipidemia and diminished levels of lipoprotein lipase activity. Hum. Mutat. 8 (1996) 319-325
9. Durrington P. Dyslipidaemia. Lancet 362 (2003) 717-731
10. Foster D.W. The role of the carnitine system in human metabolism. Ann. N Y Acad. Sci. 1033 (2004) 1-16
11. Gao G.P., Alvira M.R., Wang L., Calcedo R., Johnston J., and Wilson J.M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 99 (2002) 11854-11859
12. Glass C.K., and Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14 (2000) 121-141
13. Goldberg I.J., Scheraldi C.A., Yacoub L.K., Saxena U., and Bisgaier C.L. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J. Biol. Chem. 265 (1990) 4266-4272
14. Grefhorst A., Elzinga B.M., Voshol P.J., Plosch T., Kok T., Bloks V.W., van der Sluijs F.H., Havekes L.M., Romijn J.A., Verkade H.J., and Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 277 (2002) 34182-34190
15. Guan H.P., Ishizuka T., Chui P.C., Lehrke M., and Lazar M.A. Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev. 19 (2005) 453-461
16. Gupta S., Pandak W.M., and Hylemon P.B. LXR alpha is the dominant regulator of CYP7A1 transcription. Biochem. Biophys. Res. Commun. 293 (2002) 338-343
17. Horton J.D., Shimano H., Hamilton R.L., Brown M.S., and Goldstein J.L. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J. Clin. Invest. 103 (1999) 1067-1076
18. Horton J.D., Shah N.A., Warrington J.A., Anderson N.N., Park S.W., Brown M.S., and Goldstein J.L. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA 100 (2003) 12027-12032
19. Hu X., and Lazar M.A. Transcriptional repression by nuclear hormone receptors. Trends Endocrinol. Metab. 11 (2000) 6-10
20. Hu X., Li S., Wu J., Xia C., and Lala D.S. Liver x receptors interact with corepressors to regulate gene expression. Mol. Endocrinol. 17 (2003) 1019-1026
21. Ishibashi S., Brown M.S., Goldstein J.L., Gerard R.D., Hammer R.E., and Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92 (1993) 883-893
22. Jakel H., Nowak M., Moitrot E., Dehondt H., Hum D.W., Pennacchio L.A., Fruchart-Najib J., and Fruchart J.C. The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. J. Biol. Chem. 279 (2004) 45462-45469
23. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., and Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383 (1996) 728-731
24. Joseph S.B., McKilligin E., Pei L., Watson M.A., Collins A.R., Laffitte B.A., Chen M., Noh G., Goodman J., Hagger G.N., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 99 (2002) 7604-7609
25. Lebherz C., Gao G., Louboutin J.P., Millar J., Rader D., and Wilson J.M. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J. Gene Med. 6 (2004) 663-672
26. Levin N., Bischoff E.D., Daige C.L., Thomas D., Vu C.T., Heyman R.A., Tangirala R.K., and Schulman I.G. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 135-142
27. Levine G.N., Keaney Jr. J.F., and Vita J.A. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N. Engl. J. Med. 332 (1995) 512-521
28. Li A.C., and Glass C.K. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid Res. 45 (2004) 2161-2173
29. Liang Y., Jiang X.C., Liu R., Liang G., Beyer T.P., Gao H., Ryan T.P., Dan Li S., Eacho P.I., and Cao G. Liver X receptors (LXRs) regulate apolipoprotein AIV-implications of the antiatherosclerotic effect of LXR agonists. Mol. Endocrinol. 18 (2004) 2000-2010
30. Lin J., Yang R., Tarr P.T., Wu P.H., Handschin C., Li S., Yang W., Pei L., Uldry M., Tontonoz P., et al. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 120 (2005) 261-273
31. Mak P.A., Laffitte B.A., Desrumaux C., Joseph S.B., Curtiss L.K., Mangelsdorf D.J., Tontonoz P., and Edwards P.A. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J. Biol. Chem. 277 (2002) 31900-31908
32. McKenna N.J., and O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108 (2002) 465-474
33. Medh J.D., Fry G.L., Bowen S.L., Ruben S., Wong H., and Chappell D.A. Lipoprotein lipase- and hepatic triglyceride lipase-promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism. J. Lipid Res. 41 (2000) 1858-1871
34. Merkel, M., Loeffler, B., Kluger, M., Fabig, N., Geppert, G., Pennacchio, L.A., Laatsch, A., and Heeren, J. (2005). Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan bound lipoprotein lipase. J. Biol. Chem. Published online March 17, 2005. 10.1074/jbc.M411412200.
35. Millatt L.J., Bocher V., Fruchart J.C., and Staels B. Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. Biochim. Biophys. Acta 1631 (2003) 107-118
36. Ordovas J.M., and Corella D. Nutritional genomics. Annu. Rev. Genomics Hum. Genet. 5 (2004) 71-118
37. Pastinen T., Sladek R., Gurd S., Sammak A., Ge B., Lepage P., Lavergne K., Villeneuve A., Gaudin T., Brandstrom H., et al. A survey of genetic and epigenetic variation affecting human gene expression. Physiol. Genomics 16 (2004) 184-193
38. Peet D.J., Janowski B.A., and Mangelsdorf D.J. The LXRs: a new class of oxysterol receptors. Curr. Opin. Genet. Dev. 8 (1998) 571-575
39. Peet D.J., Turley S.D., Ma W., Janowski B.A., Lobaccaro J.M., Hammer R.E., and Mangelsdorf D.J. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93 (1998) 693-704
40. Pennacchio L.A., Olivier M., Hubacek J.A., Cohen J.C., Cox D.R., Fruchart J.C., Krauss R.M., and Rubin E.M. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294 (2001) 169-173
41. Rader D.J., Cohen J., and Hobbs H.H. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 111 (2003) 1795-1803
42. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., Shan B., Brown M.S., Goldstein J.L., and Mangelsdorf D.J. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 14 (2000) 2819-2830
43. Repa J.J., Berge K.E., Pomajzl C., Richardson J.A., Hobbs H., and Mangelsdorf D.J. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 277 (2002) 18793-18800
44. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., et al. Role of LXRs in control of lipogenesis. Genes Dev. 14 (2000) 2831-2838
45. Schuster G.U., Parini P., Wang L., Alberti S., Steffensen K.R., Hansson G.K., Angelin B., and Gustafsson J.A. Accumulation of foam cells in liver X receptor-deficient mice. Circulation 106 (2002) 1147-1153
46. Spady D.K., Cuthbert J.A., Willard M.N., and Meidell R.S. Overexpression of cholesterol 7alpha-hydroxylase (CYP7A) in mice lacking the low density lipoprotein (LDL) receptor gene. LDL transport and plasma LDL concentrations are reduced. J. Biol. Chem. 273 (1998) 126-132
47. Steffensen K.R., Neo S.Y., Stulnig T.M., Vega V.B., Rahman S.S., Schuster G.U., Gustafsson J.A., and Liu E.T. Genome-wide expression profiling; a panel of mouse tissues discloses novel biological functions of liver X receptors in adrenals. J. Mol. Endocrinol. 33 (2004) 609-622
48. Tangirala R.K., Bischoff E.D., Joseph S.B., Wagner B.L., Walczak R., Laffitte B.A., Daige C.L., Thomas D., Heyman R.A., Mangelsdorf D.J., et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA 99 (2002) 11896-11901
49. Terasaka N., Hiroshima A., Koieyama T., Ubukata N., Morikawa Y., Nakai D., and Inaba T. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536 (2003) 6-11
50. Tontonoz P., and Mangelsdorf D.J. Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 17 (2003) 985-993
51. Wagner B.L., Valledor A.F., Shao G., Daige C.L., Bischoff E.D., Petrowski M., Jepsen K., Baek S.H., Heyman R.A., Rosenfeld M.G., et al. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol. Cell. Biol. 23 (2003) 5780-5789
52. Willy P.J., Umesono K., Ong E.S., Evans R.M., Heyman R.A., and Mangelsdorf D.J. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9 (1995) 1033-1045